Clobetasol Should Not Be Used Around the Eyes
Clobetasol propionate, as a very high-potency topical corticosteroid, should be avoided in the periocular area due to significant risk of glaucoma and cataracts, despite recent development of specialized ophthalmic formulations for post-surgical use only.
Key Guidance from FDA Labeling and Guidelines
The FDA drug label explicitly warns to "avoid contact with the eyes" 1. If accidental eye contact occurs, immediate flushing with large volumes of water is required 1. This is not a casual precaution—it reflects genuine safety concerns.
The 2023 American Academy of Dermatology guidelines for atopic dermatitis management specifically state that "minimizing periocular steroid use is advised" due to unclear but concerning associations with cataracts and glaucoma 2. The 2009 psoriasis guidelines are even more direct, noting that "increased intraocular pressure, glaucoma, and cataracts have been reported with use around the eye" 3.
Why This Matters: The Evidence of Harm
Documented Ocular Complications
Case reports demonstrate that potent topical corticosteroids applied to periorbital skin can cause:
- Secondary open-angle glaucoma that may be sight-threatening 4
- Permanent damage: Intraocular pressure may not return to normal even after stopping the medication 4
- These complications occur even when the steroid is applied to the eyelid skin, not directly in the eye 4
The Mechanism of Risk
When applied to periorbital skin, clobetasol can:
- Transfer from eyelid skin into the eye through normal blinking and eye rubbing
- Absorb systemically through the thin periorbital skin
- Accumulate with repeated applications over time
A 2015 review concluded there is "evidence of harm to vision when potent topical corticosteroids are inappropriately used for prolonged periods to periorbital sites" 5.
Important Caveats and Context
The Exception: Specialized Ophthalmic Formulations
Recent studies (2026) evaluated a specialized ophthalmic nanoemulsion formulation of clobetasol 0.05% designed specifically for intraocular use after cataract surgery 6, 7. This formulation:
- Was safe and effective for post-surgical inflammation
- Did not cause meaningful IOP increases or corneal changes
- Was used for only 14 days under strict ophthalmologic supervision
- Is NOT the same as dermatologic clobetasol cream/ointment/solution
This does not change the recommendation for dermatologic formulations—these ophthalmic studies actually reinforce that only specially designed formulations with appropriate safety testing should be used near or in the eye.
Safer Alternatives for Periocular Dermatitis
For eyelid eczema or periocular inflammatory conditions:
- Use topical calcineurin inhibitors (tacrolimus, pimecrolimus) as first-line therapy for periocular areas
- A 2007 study showed tacrolimus 0.1% ointment was effective for eyelid eczema in atopic keratoconjunctivitis without affecting intraocular pressure 8
- If a corticosteroid is absolutely necessary, use only low-potency agents (hydrocortisone 1-2.5%) for brief periods
- Never use clobetasol or other very high-potency steroids
Clinical Algorithm
For periocular inflammatory conditions:
- First-line: Topical calcineurin inhibitors (tacrolimus 0.03-0.1% or pimecrolimus 1%)
- If inadequate response: Low-potency corticosteroid (hydrocortisone 1-2.5%) for ≤7 days
- If still inadequate: Refer to dermatology or ophthalmology
- Never use clobetasol or other Class I/II steroids periocularly
If clobetasol is prescribed for facial dermatitis:
- Explicitly instruct patients to avoid the periocular area (at least 1-2 cm from the eye)
- Warn about accidental eye contact
- Consider alternative agents for any lesions near the eyes
- Patients with family history of glaucoma are at higher risk 4